Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

This trial tests giving two immunotherapy drugs — cemiplimab and cetuximab — before salvage surgery in patients with oral cavity squamous cell carcinoma (mouth/jaw cancer) that has come back after prior treatment. The goal is to shrink the tumor before the operation. **You may be eligible if...** - You are 18 or older - You have been diagnosed with recurrent squamous cell carcinoma of the oral cavity (mouth cancer) - Your cancer has come back at least 3 months after completing prior curative treatment - You are a candidate for salvage surgery - Your cancer is measurable on imaging **You may NOT be eligible if...** - You are not a surgical candidate - Your cancer recurred within 3 months of completing prior treatment - You have significant other health conditions that prevent participation Talk to your doctor to see if this trial is right for you.